ConductScience.org, home

Paper880258

Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.

Müller WE and 3 others. Biochem Pharmacol, 1977. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent. Papers, record 880258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/880258

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.
PubMed
Journal
Biochem Pharmacol
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.25
iCite
Revised in PubMed
2019-06-23
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Müller WEW E
2Maidhof AA
3Taschner HH
4Zahn RKR K

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell DivisionMajor topic
RibavirinMajor topic
RibonucleosidesMajor topic
Cells, Cultured
DNA
DNA-Directed DNA Polymerase
DNA-Directed RNA Polymerases
Depression, Chemical
Drug Interactions
Guanosine Triphosphate
Polyribosomes
Protein Biosynthesis
RNA

Source PubMed

Download CSV of topics

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
37623252Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.Curr Issues Mol Biol2023https://conductscience.org/library/papers/37623252PubMed
36602354Atypical Mutational Spectrum of SARS-CoV-2 Replicating in the Presence of Ribavirin.Antimicrob Agents Chemother2023https://conductscience.org/library/papers/36602354PubMed
36358961Hydrophobic Rose Bengal Derivatives Exhibit Submicromolar-to-Subnanomolar Activity against Enveloped Viruses.Biomolecules2022https://conductscience.org/library/papers/36358961PubMed
36297288Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/36297288PubMed
34955556Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action.Mol Biol2021https://conductscience.org/library/papers/34955556PubMed
34765999Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.Mol Biomed2020https://conductscience.org/library/papers/34765999PubMed
33924302Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.Viruses2021https://conductscience.org/library/papers/33924302PubMed
33623816Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2.Inform Med Unlocked2021https://conductscience.org/library/papers/33623816PubMed
28359770Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.J Virol Methods2017https://conductscience.org/library/papers/28359770PubMed
27754363Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations.Viruses2016https://conductscience.org/library/papers/27754363PubMed
26222794Ribavirin Inhibits Parrot Bornavirus 4 Replication in Cell Culture.PLoS One2015https://conductscience.org/library/papers/26222794PubMed
22495651Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.Med Res Rev2012https://conductscience.org/library/papers/22495651PubMed
19643775Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.J Antimicrob Chemother2009https://conductscience.org/library/papers/19643775PubMed
19244331Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.J Virol2009https://conductscience.org/library/papers/19244331PubMed
17855555Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells.J Virol2007https://conductscience.org/library/papers/17855555PubMed
17060520Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.Antimicrob Agents Chemother2007https://conductscience.org/library/papers/17060520PubMed
16287208Mechanisms of action of ribavirin against distinct viruses.Rev Med Virol2006https://conductscience.org/library/papers/16287208PubMed
16131589The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro.RNA2005https://conductscience.org/library/papers/16131589PubMed
16043507Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.RNA2005https://conductscience.org/library/papers/16043507PubMed
15911031Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.Antiviral Res2005https://conductscience.org/library/papers/15911031PubMed

See all 32 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/880258

GET https://conductscience.org/api/papers/v1/880258/cited_by?page=2